Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233448 | 0.85 | KDM4E (0.36) | ALDH1A1GAANPC1KDM4EHSD17B10 | |
| SCHEMBL76231 | 0.83 | ACHE (0.48) | ALDH1A1HPGDACHEMAPTCYP3A4 | |
| Fluoride SCHEMBL28104198 | 0.80 | ACHE (0.46) | ALDH1A1HPGDACHEMAPTCYP3A4 | |
| SCHEMBL2282004 | 0.79 | GAA (0.35) | ALDH1A1GAANPC1MAPTCA9 | |
| SCHEMBL11689421 | 0.78 | L3MBTL1 (0.38) | ALDH1A1HPGDGAAMAPTMEN1 | |
| SCHEMBL2286065 | 0.77 | KDM4E (0.31) | ALDH1A1ACHEKDM4EHSD17B10 | |
| SCHEMBL2289162 | 0.77 | GAA (0.34) | ALDH1A1HPGDACHEGAANPC1 | |
| SCHEMBL14813270 | 0.77 | KDM4E (0.33) | ALDH1A1MAPTKDM4EHSD17B10MEN1 | |
| SCHEMBL2284993 | 0.76 | GAA (0.38) | ALDH1A1HPGDGAANPC1MAPT | |
| SCHEMBL1205334 | 0.76 | KMT2A (0.38) | ALDH1A1HPGDGAANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206551-A | Quinoline compounds, their preparation and their use as antimalarial agents | 美国卫生和人力服务部 | 2024-06-18 | — | — | CN | claimed |
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | claimed |
| EP-3790878-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2021-03-17 | — | — | EP | claimed |
| CN-112334468-A | Quinoline compounds, their preparation and use as antimalarial agents | 美国卫生和人力服务部 | 2021-02-05 | — | — | CN | claimed |
| WO-2019217957-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-11-14 | — | — | WO | claimed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | claimed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| CN-118206551-A | Quinoline compounds, their preparation and their use as antimalarial agents | 美国卫生和人力服务部 | 2024-06-18 | — | — | CN | disclosed |
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3790878-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-112334468-A | Quinoline compounds, their preparation and use as antimalarial agents | 美国卫生和人力服务部 | 2021-02-05 | — | — | CN | disclosed |
| US-4824851-A | Pyrimidones as cardiotonic, anti hypertensive, cerebrovascular vasodilator and anti-platelet agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0123402-B1 | PYRIMIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
| US-4746664-A | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-05-24 | — | — | US | disclosed |
| US-4612376-A | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-16 | — | — | US | disclosed |
| EP-0123402-A2 | Pyrimidine derivatives, preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885ACHE 30/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | ALDH1A1 3262/4885HPGD 1916/4885ACHE 38/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2053/4885HPGD 785/4885ACHE 30/4885 |
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | GLS2, RECQL, PYGL | ALDH1A1 866/4885HPGD 1530/4885ACHE 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.